Skip to main content

Clinical Trials Using Tremelimumab

Review the clinical trials studying tremelimumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-18 of 18

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer
Status: Active
Location: 28 locations
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Status: Active
Location: 15 locations
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Status: Active
Location: 4 locations
Tremelimumab and Durvalumab with and without Selective Internal Yttrium-90 Radioembolization before Surgery for the Treatment of Resectable Hepatocellular Carcinoma
Status: Active
Location: 4 locations
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Status: Active
Location: 6 locations
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Status: Active
Location: 2 locations
Hypofractionated Radiotherapy Followed by Durvalumab with or without Tremelimumab for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
Restorative Microbiota Therapy in Combination with Durvalumab, Tremelimumab, and Chemotherapy for the Treatment of Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Tremelimumab and Durvalumab for the Treatment of Advanced Liver Cell Cancer in Patients with Child-Pugh-B Cirrhosis
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Durvalumab and Tremelimumab with or without Chemotherapy for the Treatment of Potentially Resectable Pleural Mesothelioma
Status: Active
Location: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
Cabozantinib and Durvalumab with or without Tremelimumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Zanzalintinib with Durvalumab plus Tremelimumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma, The ZENOBIA Trial
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Yttrium-90 Radioembolization in Combination with Tremelimumab and Durvalumab for Treating Patients with Locally Advanced, Unresectable or Oligo-metastatic Intrahepatic Cholangiocarcinoma Who are Not Candidates for Curative Therapy, RAIDEN Trial
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
A Peptide Vaccine (mBTCvax) Plus Durvalumab and Tremelimumab for the Treatment of Biliary Tract Cancers
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Cryoablation and Hepatic Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab for the Treatment of Locally Advanced or Metastatic and/or Unresectable Liver cancer
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Durvalumab, and Belinostat With or Without Tremelimumab for the Treatment Metastatic or Unresectable, Locally Advanced Urothelial Carcinoma
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Durvalumab, Tremelimumab, and Selumetinib in Treating Patients with Recurrent or Stage IV Non-small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas